Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is an open-label, multicenter, extension study to evaluate the long-term safety and efficacy of BeiGene investigational drugs in participants with advanced malignancies who participated in a prior BeiGene-sponsored clinical study (parent study).
Full description
For the purposes of this study, "study treatment" will refer to all investigational agents. A parent study is defined as the original BeiGene-sponsored clinical trial in which the participant was initially enrolled and received BeiGene investigational drugs (with or without other treatments).
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Currently participating in a BeiGene-sponsored eligible parent study
Fulfills treatment criteria specified in the parent study protocol
In the opinion of the investigator, the participant will continue to benefit from and tolerate any of the parent study treatments.
The first dose of study treatment in the LTE study will be received within the treatment interruption period allowed by the parent study:
Specific Inclusion Criteria for Participants Who Continue Survival Follow-up Only in the Extension Study:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
300 participants in 18 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal